首页> 外文期刊>Pediatric blood & cancer >Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients.
【24h】

Treatment of primary CNS lymphoma with high-dose methotrexate in immunocompetent pediatric patients.

机译:大剂量甲氨蝶呤治疗小儿免疫功能正常的原发性中枢神经系统淋巴瘤。

获取原文
获取原文并翻译 | 示例
       

摘要

We report two cases of primary CNS lymphoma (PCNSL) treated with high-dose methotrexate. Though standard adult treatment of PCNSL incorporates whole-brain radiotherapy, the literature suggests it may be possible to delay or avoid radiotherapy and the associated increased risk of neurologic sequelae in pediatric patients. Studies in adults indicate methotrexate therapy can be effective against PCNSL and has advantages over the current standard of treatment. Both patients have no evidence of disease 9 and 7 years after treatment, suggesting high-dose methotrexate may lead to disease control in pediatric patients with PCNSL while avoiding the effects of radiotherapy.
机译:我们报告了两例用大剂量甲氨蝶呤治疗的原发性中枢神经系统淋巴瘤(PCNSL)。尽管成人PCNSL的标准治疗方法包括全脑放射治疗,但文献表明,可能会延迟或避免放射治疗,并伴有患儿神经系统后遗症的风险增加。成年人的研究表明,甲氨蝶呤疗法可有效对抗PCNSL,并具有优于当前治疗标准的优势。两名患者在治疗9年和7年后均无疾病迹象,这表明高剂量甲氨蝶呤可能导致PCNSL患儿的疾病得到控制,同时避免了放疗的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号